Webcast ImageWebcast
Cidara Therapeutics, Inc. Conference Call (Replay)
02/21/17 at 8:30 a.m. ET
Cidara Therapeutics, Inc. Conference Call
Tuesday, February 21, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California.


Download Documentation Corporate Presentation January 2017

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$7.55 + 0.405.59%169,036
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
02/24/17 4:00 p.m. ET
Refresh quote


Stock chart for: CDTX.O.  Currently trading at $7.55 with a 52 week high of $15.91 and a 52 week low of $6.65.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources